Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1). This peptide is strengthened with a growth factor, IGF, which has insulin-like properties.
IGF-1 LR3 insulin like growth factor
Name: IGF-1 LR3
Other Names: insulin like growth factors -1
Molar mass: 9117.5 g/mol
Place of Origin: China
Grade Standard: Medicine Grade
Appearance: white powder
Igf-1 long r3 is an 83-amino-acid analog of human IGF-I actually containing the complete human IGF-1 sequence but with the replacement of an Arg for the Glu at position 3, as well as a 13 amino acid extension peptide at the N-terminus. This makes Long R3 IGF-I significantly more potent ( 2-3x) than IGF-I in studies, because it has a lower affinity to be rendered inactive by IGF binding proteins, and consequently more potential activity in the body.
Source of active ingredients：
IGF-1 plays a significant role in muscle regeneration. Although IGF-1 induces differentiation to a much greater degree, it stimulates both proliferation and differentiation of stem cells in an autocrine-paracrine manner.
When IGF-1 is injected locally, it increases satellite cell activity, muscle DNA, muscle protein content, muscle weight and muscle cross sectional area. The importance of IGF-1 lies in the fact that all of its apparent functions act to induce muscle growth with or without overload although it really shines as a growth promoter when combined with physical loading of the muscle.
IGF-1 also acts as an endocrine growth factor having an anabolic effect on distant tissues once released into the blood stream by the liver. IGF-1 possesses the insulin-like property of inhibiting degradation, in addition it stimulates protein synthesis. The insulin-like effects are probably because of the similarity of the signaling pathways between insulin and IGF-1 following ligand binding at the receptors.
The ability of IGF-I to stimulate protein synthesis resembles the action of GH, which was shown in separate studies on volunteers to stimulate protein synthesis without affecting protein degradation. Although it is believed that the effects of GH are mediated through IGF-1, this cannot be the case entirely. First, the effects of the two hormones are different, in that GH does not change protein degradation. Second, the effect of GH is observed with little or no change in systemic IGF-1 concentrations.